MicroRNA Dysregulation in the Myelodysplastic Syndromes

Author(s): Stephen S. Chung, Christopher Y. Park

Journal Name: MicroRNA

Volume 2 , Issue 3 , 2013

Become EABM
Become Reviewer
Call for Editor


The myelodysplastic syndromes (MDS) are heterogeneous clonal disorders of ineffective hematopoiesis characterized by limited treatment options and a poor prognosis. These poor clinical characteristics stem from a poor understanding of the molecular abnormalities that drive disease pathogenesis. MicroRNAs (miRNAs) have recently been described to play wide-ranging roles in normal and malignant hematopoiesis, but very few miRNAs have been shown to be consistently dysregulated in MDS. Even fewer candidate disease miRNAs have undergone functional validation, and the clinical relevance of these miRNAs remains to be determined. Despite the fact that MDS has been shown to be a disease initiated in hematopoietic stem cells (HSC), most existing studies examining miRNA expression in MDS have used unfractionated or only partially purified bone marrow (BM) cell populations, likely explaining in part the limited insight that provided by these studies. A more robust characterization of purified disease -initiating cell populations followed by rigorous functional validation using in vivo disease models will be vital to identifying dysregulated miRNAs of functional significance in MDS. Such studies promise to provide key insights into disease pathogenesis and potentially open new avenues towards the development of therapies targeting miRNAs themselves or the pathways that they regulate.

Keywords: Bone marrow failure, hematopoietic stem cell, malignant hematopoiesis, microRNA, myelodysplasia, the myelodysplastic syndromes.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 21 January, 2014
Page: [174 - 186]
Pages: 13
DOI: 10.2174/2211536602666131126002621

Article Metrics

PDF: 44